Paid-in Capital Increase Details Amended
아리바이오LAB
261780
Signal Score
Historical Avg Return (5d)
+0.72%
Data Coverage
100%n=2270
Risk-adjusted indicator based on 2270 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Pre-increase Shares (Amended): 26,912,996 Shares
- • Payment Date (Amended): June 25, 2026
- • New Share Listing Date (Amended): July 10, 2026
- • Discount Rate for Issuance: 10%
AI Analysis Summary
CHA Vaccine Research Institute (now AriBio Lab) has amended its Material Fact Report regarding a paid-in capital increase. The pre-increase total outstanding shares were adjusted from 26,865,246 to 26,912,996 due to stock option exercises. The payment date for the new shares has been postponed from May 29, 2026, to June 25, 2026, consequently delaying the new share listing date from June 12, 2026, to July 10, 2026. The capital increase is a third-party allocation to 'Dream High Holdings' with a 10% discount rate, aiming for financial structure improvement and strategic cooperation. The new shares will be subject to a one-year lock-up period. The amendment itself is largely procedural, reflecting minor adjustments rather than a fundamental change to the capital increase plan.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.